TSHR and Jeune syndrome: Novel therapeutics which target the underlying immune dysregulation and TSH-R-Ab/TSH-R interactions may prove to be superior to inhibition of thyroid hormone synthesis by ATD in the setting of GH, when their clinical trials enter later phases of development.